New perspectives in treatment of glomerulonephritis

Pediatric Nephrology

Volumn 19, Issue 3, 2004, Pages 256-265

  Coppo, Rosanna ^a   Amore, Alessandro ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

Anti adhesion molecules; Anti CD20; Anti co stimulatory molecules; Anti COX2; Anti inflammatory cytokines; Antigen eradication; Glomerulonephritis; Mycophenolate mofetil; PPAR; Rapamycin; Thalidomide pirfenidone; Treatment

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; CD20 ANTIGEN; CORTICOSTEROID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; CYTOKINE RECEPTOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENKEPHALINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MEMBRANE METALLOENDOPEPTIDASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR B; PREDNISOLONE; RAPAMYCIN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASOPEPTIDASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CHRONIC GLOMERULONEPHRITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME INHIBITION; ERADICATION THERAPY; EXTRACELLULAR MATRIX; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FIBROSIS; KIDNEY MALFORMATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; TREATMENT PLANNING;

ANTI-INFLAMMATORY AGENTS; CHILD; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 1542300113     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-003-1357-0     Document Type: Review

References (61)

1. Cunard R, Kelly CJ (2003) Immune-mediated renal disease. J Allergy Clin Immunol 111:S637-44
2. Ardaillou R, Ronco P, Rondeau E, Friedlander G (2000) In: Brenner BM (ed) The kidney, 6th edn. Brenner and Rector's biology of renal cells in culture, vol I. WB Saunders, Philadelphia, pp 93-191
3. Abbate M, Zoja C, Corna D, Capitanio M, Bertani T, Remuzzi G (1998) In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 9:1213-1224
4. Wolf G (1998) Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant 13:1131-1142
5. Cameron JS (1977) Disease of urinary system. Treatment of glomerulonephritis by drugs. I and II. BJM 1:1457-1502
6. Hirayama K, Koyama A (2000) Mixed cryoglobulinemia associated with hepatitis C virus infection. Intern Med 39:351-352
7. Coppo R, Amore A, Hogg R, Emancipator S (2000) Idiopathic nephropathy with IgA deposits. Pediatr Nephrol 15:139-150
8. Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, Suzuki Y, Akazawa K, Shimada H, Arakawa M, Gejvo F (2003) The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy 63:1861-1867
9. Jessen RH, Emancipator SN, Jacobs GH, Nedrud JG (1992) Experimental IgA-IgG nephropathy induced by a viral respiratory pathogen. Dependence on antigen form and immune status. Lab Invest 67:379-386
10. Katz A, Dyck RF, Bear RA (1979) Celiac disease associated with immune complex glomerulonephritis. Clin Nephrol 11:39-44
11. Coppo R, Roccatello D, Amore A, Quattrocchio G, Molino A, Gianoglio B, Amoroso A, Bajardi P, Piccoli G (1990) Effects of a gluten-free diet in primary IgA nephropathy. Clin Nephrol 33:72-86
12. Coppo R, Amore A, Roccatello D, Gianoglio B, Molino A, Piccoli G, Clarkson AR, Woodroffe AJ, Sakai H, Tomino Y (1991) IgA antibodies to dietary antigens and lectin-binding IgA in sera from Italian, Australian, and Japanese IgA nephropathy patients. Am J Kidney Dis 17:480-487
13. Amore A, Cirina P, Conti G, Brusa P, Peruzzi L, Coppo R (2001) Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol 12:1862-1871
14. Hong JC, Kahan BD (2000) Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 20:108-125
15. Niaudet P, Habib R (1994) Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 5:1049-1056
16. Callis L, Vila A, Carrera M, Nieto J (1999) Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int 55:1051-1056
17. Jonsson CA, Svensson L, Carlsten H (1999) Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol 116:534-541
18. Penny MJ, Boyd RA, Hall BM (1998) Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 9:2272-2282
19. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A (1999) Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10:1542-1549
20. Ziswiler R, Steinmann-Niggli K, Kappeler A, Daniel C, Marti HP (1998) Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 9:2055-2066
21. Nowack R, Birck R, van der Woude FJ (1997) Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 15:349
22. Chen XM, Cai G, Zhang Y, Qiu Q, Cheng Q (2000) Control study of effects of mycophenolate mofetil on IgA nephropathy. J Am Soc Nephrol 11:57A
23. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA (2000) Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61:1098-1114
24. Briggs WA, Choi MJ, Scheel PJ Jr (1998) Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 31:213-217;
25. Briggs WA, Choi MJ, Scheel PJ Jr N Engl J Med 19:1156-1162
26. Hogg R, Fitzibbons L, Bruik J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R (2003) Multicenter trial of mycophenolate mofetil (MMF) in children with steroid dependent (SD) or frequent relapsing (FR) nephrotic syndrome (NS). Report of the Southwest Pediatric Nephrology Study Group. Nephrol Dial Transplant 18:261
27. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 19:1156-1162
28. Hogg R, Fitzibbons L, Hyland K (2003) Assessment of the accuracy and consistency of routine laboratory assay for serum creatinine concentrations compared to high performance liquid chromatography. Nephrol Dial Transplant 18:642
29. Saunders RN, Metcalfe MS, Nicholson L (2001) Rapamycin in transplantation: a randomized review of the evidence. Kidney Int 59:3-16
30. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC (2002) Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74:1070-1076
31. Kawasaki K, Yaoita E, Yamamoto T, Tamatani T, Miyasaka M, Kihara I (1993) Antibodies against intercellular adhesion molecule-1 and lymphocyte function-associated antigen prevent glomerular injury in rat experimental crescentic glomerulonephritis. J Immunol 150:1074-1083
32. Brey RL, Amato AA, Kagan-Hallet K, Rhine CB, Stallworth CL. Anti-intercellular adhesion molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice. Lupus 6:645-651
33. Reynolds J, Tam FW, Chandraker A, Smith J, Karkar AM, Cross J, Peach R, Sayegh MH, Pusey CD (2000) CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest 105:643-651
34. Illey GG, Czirjak L (2001) Novel approaches in the treatment of lupus nephritis. Expert Opin Investig Drugs 10:1117-1130
35. Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM (2002) Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant inflammatory disorders. Swiss Med Wkly 132:414-422
36. Hruby ZW, Shirota K, Jothy S, Lowry RP (1991) Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce immune glomerular injury. Kidney Int 40:43-51
37. Kirillova I, Chaisson M, Fausto N (1999) Tumor necrosis factor induces DNA replication in hepatic cells through nuclear factor kappaB activation. Cell Growth Differ 10:819-828
38. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS (2001) Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 44:1149-1154
39. Fisher CJ Jr, Opal SM, Lowry SF, Sadoff JC, LaBrerque JF, Donovan HC, Lookabaugh JL, Lemke J, Pribble JB, Stromatt SC (1994) Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. Circ Shock 44:1-8
40. Baud L, Fouqueray B, Bellocq A (2001) Cytokines and hormones with anti-inflammatory effects: new tools for therapeutic intervention. Curr Opin Nephrol Hypertens 10:49-54
41. Tipping PG, Kitching AR, Huang XR, Mutch DA, Holdsworth SR (1997) Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol 27:530-537
42. Kitamura M, Suto TS (1997) TGF-beta and glomerulonephritis: anti-inflammatory versus prosclerotic actions. Nephrol Dial Transplant 12:669-679
43. Arzoo K, Sadeghi S, Liebman HA (2002) Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 61:922-924
44. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455-459
45. Von Moos R, Stolz R, Cerny T, Gillessen S (2003) Thalidomide: from tragedy to promise. Swiss Med Wkly 8:77-87
46. Walchner M, Meurer M, Plewig G, Messer G (2000) Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 39:383-388
47. Duong DJ, Spigel GT, Moxley RT 3rd, Gaspari A (19999) American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 135:1079-1087
48. Peruzzi L, Gianoglio B, Porcellini MG, Coppo R (1999) Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-2 selective inhibitor nimesulide as tocolytic. Lancet 354:1615
49. Ostensen M, Villiger PM (2001) Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus 10:135-139
50. Schneider A, Harendza S, Zahner G, Jocks T, Wenzel U, Wolf G, Thaiss F, Helmchen U, Stahl RA (1999) Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis. Kidney Int 55:430-441
51. Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, Pagnoncelli M, Rottoli D, Abbate M, Remuzzi G (2001) Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 60:653-663
52. Yu HT (2003) Progression of chronic renal failure. Arch Intern Med 163:1417-1429
53. Ruggenenti P, Schieppati A, Remuzzi G (2001) Progression, remission, regression of chronic renal diseases. Lancet 357:1601-1608
54. Shihab FS, Bennett WM, Yi H, Andoh TF (2002) Pirfenidone treatment decreases transforming growth factor-beta 1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transpl 2:111-119
55. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izum T (2002) Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41:1118-1123
56. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B (1999) Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 274:32048-32054
57. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH (2000) Troglitazone halts diabetic glomerulosclerosis by blockade of mesangia expansion. Kidney Int 58:2341-2350
58. Guan Y, Breyer MD (2001) Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 60:14-23
59. Benigni A, Remuzzi G (1999) Endothelin antagonists. Lancet 9:133-138
60. Weber MA (2001) Vasopeptidase inhibitors. Lancet 3:1525-1532
61. Taal MW, Nenov VD, Satyal SR, Wong W, Sakharova O, Choi JH, Troy JL, Brenner BM (2000) Vasopeptidase inhibition affords greater renoprotection than ACE inhibition alone in rats with established nephropathy after 5/6 nephrectomy. J Am Soc Nephrol 11:631A